Recent

% | $
Quotes you view appear here for quick access.

Valeant Pharmaceuticals International, Inc. Message Board

buysvalueact 3 posts  |  Last Activity: Jan 5, 2016 11:30 PM Member since: Sep 11, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Good luck with your views

    by b0bcatman Jan 5, 2016 10:57 PM
    buysvalueact buysvalueact Jan 5, 2016 11:30 PM Flag

    First the new CEO will bring in his team of experts/direct reports with expensive pay packages
    Then there will be a top down "strategic review"
    Then there will be reductions in guidance
    Then there will be changes in accounting procedures
    Then there will be earnings re-statements
    Then there will be "non cash" asset impairment charges
    Some where in there will be congressional hearings
    There will also be FTC investigations into price fixing
    Oh and they will need to roll over some of that debt
    And lest we forget... they will need a new growth strategy since the last one wont work anymore

    None of this is good for the stock price in the short or intermediate term.

  • Is the bench strength at VRX so poor that they can't find a Senior VP (or Board Member) that can speak at an Investor's conference? The fact that Pearson can't find a qualified internal candidate to give an investor's presentation should be cause for serious concern to investors.

    The fact that JPM is willing to go along with this - rather than simply telling VRX to present another time - speaks very poorly of their objectivity as well.

    This stinks.

  • Reply to

    Pershing stakes in Valeant stock

    by lotusprince24x7 Jan 3, 2016 1:42 PM
    buysvalueact buysvalueact Jan 3, 2016 4:13 PM Flag

    Good points, and tax loss selling is clearly a valid strategy - I did some of it myself at the end of the year in some other names. However, I don't recall Ackman's funds engaging in tax loss selling in the past. Perhaps he did, I just don't recall it. He certainly has had underwater positions at the end of the year before. Ackman might be under pressure from the shareholders in his funds or perhaps there are other factors. However, of all the things that don't quite smell right at VRX, Ackman's tax loss selling is the least of the concerns.

VRX
89.63-6.96(-7.21%)Feb 8 4:01 PMEST